There are limited data regarding donor hepatocyte engraftment into recipient liver after human hepatocyte transplantation (HHTx). We reviewed the explant livers of seven children with metabolic disorders [ornithine-transcarbamylase deficiency (one), coagulation factor VII deficiency (three), Crigler-Najjar syndrome (one), progressive familial intrahepatic cholestasis type 2 (PFIC-2) deficiency (two)] who received allograft hepatocytes by intraportal infusion with improvement in phenotype, although all later underwent liver transplantation (LT). Immunohistochemistry for bile salt export protein (BSEP) in the PFIC-2 patients and genetic typing following laser capture microdissection (LCM) of liver cells in the others were used to identify donor hepatocytes in recipient explant livers. Explant livers usually showed a preserved lobular architecture. In one patient, hepatocytes were identified inside portal vein thrombi. No donor hepatocytes in liver cell plates were identified immunohistochemically or by genetic typing. HHTx was generally followed by partial recovery of metabolic function; the procedure was well tolerated; any increase in portal vein pressure was transient. Hepatocytes were identified in portal vein thrombi, even months after portal vein infusion. Further studies are needed to monitor donor hepatocytes in vivo, to quantify better the efficacy of the procedure and to find ways of improving engraftment and function.
INTRODUCTION
cyte infusion reduced hyperbilirubinemia in four patients with Crigler-Najjar syndrome type 1 (1, 8, 13) , factor VII requirements in two brothers affected by Human hepatocyte transplantation (HHTx) is being evaluated as a treatment for liver-based metabolic disor-coagulation factor VII deficiency (6) , and pipecolic acid levels in a patient with Refsum's disease (23) . It also ders and acute liver failure. Several potential advantages make HHTx attractive: the procedure is minimally inva-improved glucose control in two patients with glycogen storage disease, and improved NH 3 control in three pa-sive; cryopreserved hepatocytes allow scheduled or emergency HHTx; hepatocytes from a single donor can be tients with ornithine trancarbamylase deficiency and one patient with citrullinemia (7, 12, 20) . infused into multiple recipients; HHTx could be combined with ex vivo genetic or immunological manipula-Identification of donor hepatocytes and/or their function in recipient livers may provide valuable information tion; and the costs are much lower than those of liver transplantation (LT). However, HHTx is still in its in-in understanding the mechanisms of donor hepatocyte engraftment. As opposed to animal models in which spe-fancy. According to a recent review (7) , HHTx experience worldwide includes 21 patients with metabolic dis-cifically engineered cells or genetic labels allow distinction between donor and recipient hepatocytes, demon-ease, 20 patients with chronic liver failure, and 37 patients with acute liver failure. stration of donor hepatocyte engraftment in humans is limited to identification of the metabolic product, pro-The efficacy of HHTx in patients with inborn errors of metabolism is usually measured by recovery of the tein, or enzyme deficiency in the native liver, identification of donor sex chromosome or HLA antigens in in-deficient metabolic function. Intraportal human hepato-1404 QUAGLIA ET AL. stances of donor-recipient gender or HLA mismatch, or culin; orcein; Perls' and periodic acid-Schiff technique after diastase digestion) were also conducted as appro-genetic typing. Donor hepatocytes can be visualized directly by histochemistry, immunohistochemistry, or in priate. Parallel sections of selected samples were immunostained for hepatocyte-associated antigen OCH1E5 situ hybridization or indirectly by molecular techniques using DNA extracted from tissue samples.
(monoclonals, Dako, Ely, UK), and using a polyclonal antibody, against carcinoembryonic antigen (p-CEA) Six of the 21 patients with inborn errors of metabolism quoted in the recent review by Fisher and Strom (7) (Dako) to demonstrate hepatocytes within venous thrombi.
In the two instances of PFIC-2 disease, immunostaining are from our institution (4) (5) (6) 13, 20) . All six eventually underwent LT. Two further patients have received intra-for bile salt export pump (BSEP) was conducted as described previously (15), to identify donor hepatocytes portal hepatocyte infusions at King's College Hospital, and one has also undergone LT. We here report our find-within liver cell plates by demonstrating canalicular expression of BSEP, lacking in native liver. In the other ings in the livers removed at LT in these seven patients and review current understanding of hepatocyte engraft-five patients, engraftment of donor hepatocytes into recipient liver cell plates was investigated using laser mi-ment and function.
crodissection and genetic typing.
MATERIALS AND METHODS

Laser Capture Microdissection (LCM) Hepatocyte Transplantation
Twenty-four hours before microdissection, frozen Human hepatocytes were isolated from unused donor sections at 10 µm were cut from samples of explant liver livers or tissues using a collagenase digestion technique stored at −80°C, and mounted onto UV pretreated in the Good Manufacturing Practice laboratory under PALM Membrane slides. The frozen sections and parafsterile conditions. Cells were either infused into the pafin sections were stained with H&E. No coverslip was tient immediately or were cryopreserved for subsequent applied and the glass slides bearing the tissue sections use.
were kept inside a sterile plastic envelope and stored at Cell infusions were with ABO-compatible hepato-−20°C until the time of microdissection. LCM was carcytes, with up to 100 million cells per kg body weight ried out using a noncontact laser microdissection and infused directly into the liver via the portal vein. Portal pressure catapulting system (PALM microlaser technolpressure was monitored during cell administration. In ogies, Carl Zeiss Ltd, Welwyn Garden City, UK) based some patients repeated infusions were performed to adon an inverted Axiovert 200 microscope (Zeiss). Liver minister up to 5% of the recipient hepatocyte cell mass.
cell plates were microdissected from tissue sections us-The immunosuppression regimen used was similar to ing the PALM Robosoftware graphic tool. The graphic that given to whole organ transplant recipients.
tool was used to outline groups of 2-10 plate-forming Post-HHTx Recipient Liver Biopsy Specimens hepatocytes. The outline was kept well clear of the sinusoidal hepatocyte pole, so that the laser beam would In patient 1 needle liver biopsies were performed 2 not include endothelial or intrasinusoidal cells in the miand 10 weeks after hepatocyte transplantation. Part of crodissected area. One hundred areas chosen randomly these biopsy samples were snap-frozen and stored at were microdissected from each section of each patient. −80°C, and subsequently used for DNA extraction, Microdissected target areas were catapulted into the quantification, and analysis (see below). mineral oil-filled cap of an Eppendorf tube. At the end Post-HHTx Explant Liver Histology of the microdissection the Eppendorf tube was closed and centrifuged for 1 min. All patients in the study subsequently underwent organ transplantation at different times after hepatocyte DNA Extraction transplantation. Explant livers were delivered to our laboratory immediately after removal from the patient in The laser dissection samples underwent DNA extraction using phenol/chloroform. Thirty microliters of 10 the operating theater and were promptly sliced and examined. Samples of liver parenchyma were frozen and mg/ml proteinase K (Sigma-Aldrich, Gillingham, Dorset, UK) was added to the sample and incubated at 56°C stored at −80°C, when possible. In patient 1, who underwent auxiliary liver transplantation, liver tissue was for 3 h. In the case of formalin-fixed paraffin-embedded tissue, the samples were incubated at 70°C for 10 min taken from nine different areas of the explanted left lateral segment. Parallel samples fixed in buffered formalin to melt the paraffin wax. They were then incubated with proteinase K for 4 h before phenol/chloroform extrac-and samples of hilar structures obtained for routine histological diagnosis were routinely processed, sectioned tion. Phenol (400 µl, pH 8) was added and the sample agitated and then centrifuged at 13,000 rpm for 3 min. at 5 µm, and stained with haematoxylin/eosin (H&E). Other staining (Gordon and Sweet technique for reti-
The upper aqueous layer was transferred into a sterile Eppendorf tube and 400 µl of buffered phenol/chloro-tension was observed at the last follow-up before LT in the non-PFIC-2 patients. form/isoamylalcohol (25:24:1) was added; the tube was agitated and centrifuged. The upper aqueous layer was Patient 1 (OTC deficiency) improved significantly after infusion of 1.9 billion hepatocytes into the portal transferred into a sterile Eppendorf and 400 µl of chloroform/isoamylalcohol (24:1) was added, agitated, and vein, in terms of blood ammonia levels and increase in serum urea while on a normal protein diet. The patient centrifuged. The upper aqueous layer was transferred into a sterile labeled Eppendorf tube and 1000 µl of cold underwent successful left lobe auxiliary transplantation at 7 months of age due to the long-term uncertainties on (−20°C) absolute ethanol was added to the DNA extract. This was incubated at −20°C for a minimum of 30 min.
the efficacy of hepatocyte transplantation. Patient 2 was a member of the same family as patients 3 and 5 and DNA was recovered by centrifugation at 13,000 rpm for 15 min. The ethanol supernatant was removed and 500 showed reduction in factor VII requirement at follow-up 3 months after infusion of 2.18 billion hepatocytes into µl of 70% ethanol was added followed by gentle inversion to mix; the mixture was then centrifuged at 13,000 the inferior mesenteric vein. He underwent orthotopic liver transplantation ϳ6 months after hepatocyte infu-rpm. The ethanol supernatant was removed and the DNA pellet was allowed to dry. The pellet was resus-sion. Patients 3 and 5 were two brothers with severe inher-pended in 30 µl of sterile distilled water. Samples were stored at 4°C.
ited coagulation factor VII (FVII) deficiency who had infusion of 1.1 and 2.2 billion hepatocytes, respectively, Reference samples were extracted from blood samples from the recipients and donor liver tissue biopsies in the inferior mesenteric vein. The coagulation defect improved with requirement for exogenous factor VII using Qiagen QIAamp DNA Mini kit (Qiagen Ltd, Crawley, UK) as per the manufacturer's instructions.
(rFVIIa) reducing to ϳ20% of that before cell transplantation. However, after 6 months increasing requirement for higher doses of rFVIIa suggested loss of transplanted DNA Quantification hepatocyte function. Both children underwent orthotopic DNA was quantified using a Nanodrop spectropholiver transplantation successfully. tometer (Nanodrop Technologies, Wilmington, DE).
Patient 4 received infusion of 4.34 billion hepatocytes through the inferior mesenteric vein for Crigler-Genetic Identification Najjar syndrome and showed reduction of bilirubin by DNA was amplified using the Promega PowerPlex more than 50% with less phototherapy. A decrease in 16 System (Promega Corporation, Madison, WI). This function of transplanted hepatocytes was observed after system simultaneously amplifies 16 STR loci. These loci 7 months. His immunosuppression was stopped and he are highly polymorphic and can be used to distinguish underwent liver transplantation 1 month later. A bile between individuals with a DNA mixture detection limit specimen obtained at the operation contained bilirubin of 1:20. Samples were amplified following the manufacglucuronides conjugates, indicating presence and functurer's protocol. The amplified samples were run on an tion of transplanted cells up to 8 months. ABI PRISM 310 genetic analyzer (Applied Biosys-Patients 6 and 7 were affected by PFIC-2, charactertems, Foster City, CA), as described in the manufacturized by deficiency of the BSEP. The other patients underwent whole liver transplanta-between each infusion, and the baseline peak and postinjection portal pressures are shown in Table 2 . LT was tion. The explant liver from patient 2 showed smooth capsular and cut surfaces. The portal vein was patent. performed at a median of 197 days (range 40-433) after the last hepatocyte infusion. Six of the patients under-Microscopically, the lobular architecture was preserved.
There was a minimal and nonspecific portal and lobular went orthotopic LT and one patient underwent auxiliary LT. No clinical or radiological evidence of portal hyper-lymphocytic infiltrate. The explant liver from patient 3 showed atrophy of patent macroscopically. Microscopically, the lobular architecture was preserved. There was a moderate portal/ the left lobe. The main portal vein was patent. The right lobe was unremarkable macroscopically. Microscopi-lobular lymphocytic infiltrate. Both livers from patients 6 and 7 were cirrhotic with mild inflammatory activity cally, the right lobe lobular architecture was preserved. There was a mild predominantly portal lymphocytic in-and cholestasis. The liver of patient 6 contained also a 5-mm-diameter hepatocellular carcinoma (15). filtrate.
The explant liver from patient 4 showed some areas Livers from the patients with disorders other than PFIC-2 had thrombi in peripheral intrahepatic radicles of discoloration in the caudate lobe and segments VI/ VII. Microscopically, the lobular architecture was pre-of the portal vein; four livers had thrombi in hilar portal vein branches (patients 1, 3, 4 and 5) ( Figs. 1, 2, 3 , served. There was a marked portal-lobular and subcapsular predominantly lymphocytic infiltrate. and 4). In one patient many multinucleated macrophages were found within the thrombus (patient 1) ( Fig. 1) . In The explant liver from patient 5 showed smooth capsular and homeogenous cut surfaces of the right lobe another of these (patient 5) ( Fig. 3 ) the thrombus contained hepatocytes, as confirmed immunohistochemi-and some atrophy of the left lobe. The portal vein was
DNA Studies
Frozen tissue was available in four of the five non-PFIC-2 explants (i.e., patients 1, 3, 4, and 5). Unfortunately there were no frozen sections available with portal vein thrombi containing hepatocytes for study. LCM was carried out successfully on sections from the explant livers of these four patients. DNA was isolated from all microdissected samples. Three DNA samples (patients 3, 4, and 5) were amplified successfully. DNA amplification failed in patient 1. There was no evidence of donor hepatocytes integrated into recipient liver cell plates by LCM and genetic typing, as shown for patient 5 as an example in Figure 6 .
Microdissection of 15 serial paraffin sections containing hepatocytes entrapped into portal thrombi (patient 5) was carried out. However, a minimal amount of DNA In patient 1 no donor DNA could be detected in the two liver biopsies 2 and 10 weeks after HHTx. Similarly, no donor DNA was detected in the nine tissue cally by their expression of hepatocyte-associated antisamples from the left lateral segment of the explant liver gen (Fig. 3c ) and formation of canaliculi (Fig. 3d ). The of patient 1. thrombi were associated with a predominantly lympho-DISCUSSION histiocytic inflammatory infiltrate in two livers (patients 4 and 5) ( Fig. 5 ). In our experience and that of others
In this article we have reviewed the livers removed (16), these changes are not observed in livers affected at LT from seven patients who underwent HHTx in our by these metabolic disorders when removed at transplancenter. In the non-PFIC-2 patients there was initial retation without prior hepatocyte infusion.
covery of the deficient metabolic function with improve-BSEP expression could not be demonstrated immument in terms of ammonia and urea levels (OCT patient), nohistochemically in either of the two PFIC-2 livers or requirement for exogenous factor VII (factor VII-defiin the hepatocellular carcinoma; microsatellite-haplocient patients), and bilirubin level (Crigler-Najjar patype analysis of DNA extracted from the tumour also tient). There was no clinical adverse effect following the demonstrated native origin (15). procedure, which was well tolerated by all patients.
There was a transient increase in portal vein pressure following each infusion. None of the five patients with non-PFIC-2 disease had evidence of portal hypertension at the time of transplantation. The explant livers showed an intact architecture with the exception of two livers showing atrophic changes of the left lobe and the two cirrhotic livers from the PFIC-2 patients. The rationale for hepatocyte transplantation in these two cirrhotic patients was that the architectural injury secondary to the primary condition could have favored repopulation of the liver by donor hepatocytes. However, liver transplantation probably remains the best option for these cirrhotic patients as it also removes the risk for development of hepatocellular carcinoma. We identified hepatocyte thrombi in the portal vein branches of one liver. With the limitations of the techniques used and the time of tissue sampling after transplantation, we found no direct evidence of donor hepato- portal vein branches without integration into liver cell of endothelium by cyclophosphamide facilitates hepatocyte engraftment in rats (18) . Full integration into liver plates.
Hepatocyte engraftment following hepatocyte infu-cell plates with connection to the biliary tree is achieved in 3-7 days (11), at which point the engrafted hepato-sion has been extensively investigated in animal models [for review see (10) ]. Hepatocytes injected directly into cyte may be able to proliferate (10) . Hepatocytes dwelling inside the portal vein/sinusoi-the portal vein or into the splenic substance can stream through to the smallest branches of the portal vein, dal lumen may be removed by phagocytic cells. Inhibition of Kupffer cell function has been demonstrated to where they translocate into the periportal sinusoids through a size-limited mechanical process that in normal facilitate hepatocyte engraftment (14). This model of hepatocyte engraftment is derived conditions impedes transfer to the sinusoidal space deep in the lobule. This limitation can be overcome by the from extensive animal studies, but evidence that a similar process occurs in humans is scant. In our series we use of hepatic sinusoidal vasodilators (22). Portal hypertension has been shown to be transient (10) .
have observed clusters of hepatocytes wedged into small portal vein branches, as well as fibrous obliteration of Arrival in the sinusoids is followed by adhesion to endothelial cells and transmigration through the endo-venular and venous lumina and recanalized thrombus or recently deposited thrombus within small and large por-thelium to integrate into liver cell plates (11) . Disruption hepatocyte engraftment (8-12 months after portal hepatocyte infusion) by fluorescent in situ hybridization (FISH) for the Y chromosome sequences and tissue argininosuccinate lyase activity.
In a report by Bilir et al. (3) on hepatocyte transplantation in five patients with acute liver failure, donor male hepatocytes identified by FISH for Y chromosome sequences seemed to be integrated into liver parenchyma. Analogous findings were reported in abstract form by Soriano et al. (24) .
Indirect evidence of engraftment derives from three other recent studies. Sokal infusion in a patient with Crigler-Najjar syndrome provides indirect evidence of hepatocyte engraftment with tal vein branches. In two patients architectural changes communication with the biliary tree (8). Mas et al. demwithin the liver consistent with effects of impaired portal onstrated donor hepatocyte engraftment by short tandem venous inflow were also present. Portal pressure increased repeats analysis (19) in tissue obtained from two acute almost invariably during hepatocyte infusion ( Table 2) . liver failure patients, 1 to 2 days after intrahepatic hepa-However, the baseline portal pressure before the followtocyte infusion. In contrast, Ambrosino et al.
(1) could ing infusion was usually lower and within normal limits, not demonstrate chimerism by short tandem repeat analindicating that the infusion portal pressure peak was ysis of biopsy material in Crigler-Najjar syndrome 40 usually transient. days or in the explant liver 146 days after hepatocyte In humans, evidence of donor hepatocyte engraftment infusion. with integration into recipient liver cell plates has been
In the present study we have not been able to demonprovided in a few studies (Table 3 ). Grossman et al.
strate engraftment of donor hepatocytes into liver cell visualized engrafted hepatocytes 4 months after autoplates in explant livers. Our patients underwent LT sevtransplant of ex vivo LDL receptor transduced hepatoeral months after donor hepatocyte infusion, at which cytes by in situ hybridization (9) . In a 3.5-year-old girl time donor hepatocytes may be much reduced in numwith argininosuccinate lyase deficiency, Stephenne et al. ber. In only one patient were liver biopsy specimens (25) have recently demonstrated sustained male donor available after hepatocyte infusion. As all donors were, by chance, gender matched to recipients, in situ hybridization for Y chromosome sequences could not be used to track mismatches. Despite numerous attempts, we could not reliably demonstrate factor VII in normal liver immunohistochemically (data not shown); this precluded identification of infused hepatocytes that synthesized factor VII. Genetic typing found no donor DNA in liver cell plates isolated by LCM. There had been preliminary data from the explant liver of patient 4, which suggested that small amounts of DNA (0.18 ± 0.13%) were detectable, but this could not be confirmed in the present study. In addition, the liver biopsy samples from patient 1 had also been previously analyzed (21) and, as in the present study, no donor DNA was detected. The technique we used is fairly sensitive, with a DNA mixture detection limit of 5% from dilution studies (17), so we cannot exclude the presence of donor hepatocyte DNA below this sensitiv- ity threshold, or more likely sampling error. However, Four of the five "non-PFIC-2" livers showed a portal/ lobular hepatitic process. The most severe example was as most of the patients had multiple cell donors, it makes it more difficult to detect the individual contribution at observed in patient 4, in whom immunosuppression was stopped 2 weeks before LT, such that in this patient in-this level of detection. It was hoped that direct dissection of the microthrombi-containing hepatocytes would in-flammation is likely to reflect rejection. However, a similar hepatitic process was observed in the other three crease the relative donor DNA content in the sample. Unfortunately, technical issues related to the use of paraffin-patients still on immunosuppression at LT. Further studies are needed to elucidate the cause and significance of embedded tissue did not make this possible. Further improvements of the technique are needed to isolate enough this process.
In conclusion, clinicopathological review of our ex-DNA, which can be successfully amplified by PCR.
If in humans integration of infused hepatocytes into perience in HHTx shows that in patients other than those with PFIC-2 there is initial recovery of metabolic func-liver cell plates is an infrequent and possibly focal phenomenon, it is reasonable to speculate that part of the tion; the procedure is well tolerated; the increase in portal vein pressure is transient and no portal hypertension recovery of metabolic function could be attributed to surviving donor hepatocytes wedged into small branches is present at the time of liver transplantation. Explant livers in general show a preserved lobular architecture of the portal vein as described in patient 5 and reported by other centers (2, 3) . Human hepatocyte suspensions and portal vein thrombi (some of which contain hepatocytes) predominantly in small intrahepatic portal vein have tissue factor-dependent procoagulant activity (26), which could fit with our findings, with activation of co-branches. Further studies are needed to monitor donor hepato-agulation being the trigger of the inflammatory reaction noted in these thrombi. cytes in vivo, to better quantify the efficacy of the proce- function.
